| A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults (NCT05901636) | Janssen Vaccines & Prevention B.V. | 2023-05-17 |
| A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older (NCT05327816) | Janssen Vaccines & Prevention B.V. | 2022-04-13 |
| A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults (NCT05091307) | Janssen Vaccines & Prevention B.V. | 2021-11-02 |
| A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years (NCT05101486) | Janssen Vaccines & Prevention B.V. | 2021-11-01 |
| A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old (NCT05083585) | Janssen Vaccines & Prevention B.V. | 2021-10-08 |
| A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection (NCT05070546) | Janssen Vaccines & Prevention B.V. | 2021-09-29 |
| A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive (NCT05007080) | Janssen Vaccines & Prevention B.V. | 2021-09-27 |
| A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (NCT04765384) | Janssen Vaccines & Prevention B.V. | 2021-08-27 |
| A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2 (NCT04999111) | Janssen Vaccines & Prevention B.V. | 2021-08-06 |
| A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older (NCT04908683) | Janssen Vaccines & Prevention B.V. | 2021-07-21 |
| A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults (NCT04908722) | Janssen Vaccines & Prevention B.V. | 2021-06-18 |
| A Study of Ad26.COV2.S in Healthy Adults (COVID-19) (NCT04894305) | Janssen Vaccines & Prevention B.V. | 2021-05-25 |
| A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (NCT04614948) | Janssen Vaccines & Prevention B.V. | 2020-11-12 |
| A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women (NCT04556526) | Janssen Vaccines & Prevention B.V. | 2020-10-05 |
| A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (NCT04505722) | Janssen Vaccines & Prevention B.V. | 2020-09-07 |
| A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents (NCT04535453) | Janssen Vaccines & Prevention B.V. | 2020-08-28 |
| A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults (NCT04453202) | Janssen Vaccines & Prevention B.V. | 2020-07-16 |
| A Study of Ad26.COV2.S in Adults (COVID-19) (NCT04436276) | Janssen Vaccines & Prevention B.V. | 2020-07-15 |
| A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants (NCT04228783) | Janssen Vaccines & Prevention B.V. | 2020-02-18 |
| A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (NCT03964415) | Janssen Vaccines & Prevention B.V. | 2019-10-31 |
| A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants (NCT03929757) | Janssen Vaccines & Prevention B.V. | 2019-08-19 |
| A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older (NCT03982199) | Janssen Vaccines & Prevention B.V. | 2019-08-01 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age (NCT03606512) | Janssen Vaccines & Prevention B.V. | 2019-01-21 |
| A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults (NCT03795441) | Janssen Vaccines & Prevention B.V. | 2019-01-07 |
| Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix (NCT03610581) | Janssen Vaccines & Prevention B.V. | 2018-09-27 |
| A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule (NCT03566940) | Janssen Vaccines & Prevention B.V. | 2018-07-31 |
| A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older (NCT03502707) | Janssen Vaccines & Prevention B.V. | 2018-07-06 |
| A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment (NCT03307915) | Janssen Vaccines & Prevention B.V. | 2018-03-05 |
| A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health (NCT03339713) | Janssen Vaccines & Prevention B.V. | 2017-12-07 |
| A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (NCT03303625) | Janssen Vaccines & Prevention B.V. | 2017-11-29 |
| A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers (NCT03356561) | Janssen Vaccines & Prevention B.V. | 2017-11-26 |
| A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa (NCT03060629) | Janssen Vaccines & Prevention B.V. | 2017-11-03 |
| An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults (NCT03334695) | Janssen Vaccines & Prevention B.V. | 2017-10-16 |
| A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults (NCT03032588) | Janssen Vaccines & Prevention B.V. | 2017-10-09 |